Update date
27 Feb 2026
REGENTIS BIOMATERIALS LTD. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
- Symbol
- RGNT on NYSE
- Location
- Or Akiva
- Fiscal year end
- 31 December
- Latest financial report
- 27 Feb 2026
Shareable Research Card
RGNT - REGENTIS BIOMATERIALS LTD. Financial Facts
RGNT - REGENTIS BIOMATERIALS LTD. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q4 2025
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Dec 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for RGNT - REGENTIS BIOMATERIALS LTD.
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 27 Feb 2026.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- RGNT - REGENTIS BIOMATERIALS LTD. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
See Original Filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 5,179,378 | |
| Common Stock, Shares, Outstanding | 5,179,378 | +3093% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY change |
|---|---|---|
| Accrued Liabilities, Current | $1,393,000 | +24% |
| Additional Paid in Capital | $60,538,000 | +5710% |
| Assets | $7,618,000 | +1480% |
| Cash and Cash Equivalents, at Carrying Value | $7,378,000 | |
| Common Stock, Shares Authorized | 22,500,000 | +14% |
| Common Stock, Shares, Issued | 5,179,378 | +3093% |
| Deferred Tax Assets, Gross | $11,109,000 | +24% |
| Deferred Tax Assets, Operating Loss Carryforwards | $48,300,000 | +24% |
| Deferred Tax Assets, Valuation Allowance | $11,109,000 | +24% |
| Liabilities | $2,874,000 | -56% |
| Liabilities and Equity | $7,618,000 | +1480% |
| Liabilities, Current | $2,874,000 | -56% |
| Other Assets, Current | $240,000 | -5.1% |
| Retained Earnings (Accumulated Deficit) | $55,794,000 | -32% |
| Stockholders' Equity Attributable to Parent | $4,744,000 |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first